In vitro development of a vascularized full thickness skin equivalent model

2016 ◽  
Vol 07 (03) ◽  
Author(s):  
Andrew Sumagaysay Ramos
2021 ◽  
Vol 22 (23) ◽  
pp. 12788
Author(s):  
Subin Jeong ◽  
Jisue Kim ◽  
Hye Mi Jeon ◽  
Kyunghee Kim ◽  
Gun Yong Sung

The skin is subject to both intrinsic aging caused by metabolic processes in the body and extrinsic aging caused by exposure to environmental factors. Intrinsic aging is an important obstacle to in vitro experimentation as its long-term progression is difficult to replicate. Here, we accelerated aging of a full-thickness skin equivalent by applying periodic mechanical stimulation, replicating the circadian rhythm for 28 days. This aging skin model was developed by culturing a full-thickness, three-dimensional skin equivalent with human fibroblasts and keratinocytes to produce flexible skin-on-a-chip. Accelerated aging associated with periodic compressive stress was evidenced by reductions in the epidermal layer thickness, contraction rate, and secretion of Myb. Increases in β-galactosidase gene expression and secretion of reactive oxygen species and transforming growth factor-β1 were also observed. This in vitro aging skin model is expected to greatly accelerate drug development for skin diseases and cosmetics that cannot be tested on animals.


2012 ◽  
Vol 12 (12) ◽  
pp. 1627-1636 ◽  
Author(s):  
Evangelia Bellas ◽  
Miri Seiberg ◽  
Jonathan Garlick ◽  
David L. Kaplan

Author(s):  
Angela Rossi ◽  
Antje Appelt-Menzel ◽  
Szymon Kurdyn ◽  
Heike Walles ◽  
Florian Groeber

2020 ◽  
Author(s):  
Shuang Lin ◽  
Xiaoning He ◽  
Yuanjia He

Abstract Background The repair of large-scale full-thickness skin defects represents a challenging obstacle in skin tissue engineering. To address the most important problem in skin defect repair, namely insufficient blood supply, this study aimed to find a method that could promote the formation of vascularized skin tissue. Method The phenotypes of ASCs and EPCs were identified respectively, and ASCs/EPCs were co-cultured in vitro to detect the expression of dermal and angiogenic genes. Furthermore, the co-culture system combined with dermal extracellular matrix hydrogel was used to repair the full-scale skin defects in rats.Result The co-culture of ASCs/EPCs could increase skin and angiogenesis-related gene expression in vitro. The results of in vivo animal experiments demonstrated that the ASCs/EPCs group could significantly accelerate the repair of skin defects by promoting the regeneration of vascularized skin.Conclusion It is feasible to replace traditional single seed cells with ASC/EPC co-culture system for vascularized skin regeneration. This system could ultimately enable clinicians to better repair the full-thickness skin defects and avoid donor site morbidity.


2021 ◽  
Vol 8 ◽  
Author(s):  
Miguel Luis Obaíd ◽  
Juan Pablo Camacho ◽  
Marianne Brenet ◽  
Rocío Corrales-Orovio ◽  
Felipe Carvajal ◽  
...  

Insufficient oxygen supply represents a relevant issue in several fields of human physiology and medicine. It has been suggested that the implantation of photosynthetic cells can provide oxygen to tissues in the absence of a vascular supply. This approach has been demonstrated to be successful in several in vitro and in vivo models; however, no data is available about their safety in human patients. Here, an early phase-1 clinical trial (ClinicalTrials.gov identifier: NCT03960164, https://clinicaltrials.gov/ct2/show/NCT03960164) is presented to evaluate the safety and feasibility of implanting photosynthetic scaffolds for dermal regeneration in eight patients with full-thickness skin wounds. Overall, this trial shows that the presence of the photosynthetic microalgae Chlamydomonas reinhardtii in the implanted scaffolds did not trigger any deleterious local or systemic immune responses in a 90 days follow-up, allowing full tissue regeneration in humans. The results presented here represent the first attempt to treat patients with photosynthetic cells, supporting the translation of photosynthetic therapies into clinics.Clinical Trial Registration:www.clinicaltrials.gov/ct2/show/NCT03960164, identifier: NCT03960164.


Sign in / Sign up

Export Citation Format

Share Document